title: Inferior vena cava replacement: the role of antiplatelet therapy.
abstract: To evaluate the effect of ibuprofen on early thrombus formation following inferior vena cava (IVC) replacement, a 4-cm segment of IVC was replaced with a 5-cm (10-mm-i.d.) segment of reinforced polytetrafluoroethylene (PTFE) graft in 12 dogs. Autologous platelets and canine fibrinogen were labeled with 111In and 125I, respectively, and injected into each animal 24 hr prior to vena cava replacement. Six dogs served as controls and six were treated with 12.5 mg/kg ibuprofen intravenously 1 hr preoperatively. All dogs were heparinized with 100 U/kg intravenous heparin prior to crossclamping the IVC: heparin was not reversed at the end of the procedure. Three hours after normal circulation was restored, the grafts were removed and counts of radioactivity made. All grafts were patent. The mean platelet count for the control group was 12.8 X 10(6)/mm2, while in the grafts from the treated group it was 0.960 X 10(6)/mm2. The decreased platelet deposition was significant in all graft segments (P less than 0.01). Fibrin deposition was reduced from 3.38 micrograms/mm2 to 0.25 micrograms/mm2 (P less than 0.01) by ibuprofen. Although fibrin and red blood cells are the major constituents of venous thrombi, platelet aggregation appears to play an important role if prosthetic material is implanted into the venous system. Ibuprofen not only reduced platelet deposition by 13.5-fold, but also reduced fibrin deposition by 13.5-fold. The ratio of platelets to fibrin in control and treated animals was similar (3.84 and 3.79, respectively). These data suggest that antiplatelet medication combined with heparin therapy might decrease early thrombus formation in venous prostheses.
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000648:ultrastructure; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D004285:Dogs; D004912:Erythrocytes / Q000648:ultrastructure; D005337:Fibrin / Q000032:analysis; D007052:Ibuprofen / Q000008:administration & dosage*; D010974:Platelet Aggregation / Q000187:drug effects*; D011138:Polytetrafluoroethylene / Q000009:adverse effects; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology; D014682:Vena Cava, Inferior / Q000601:surgery
chemical_list: D005337:Fibrin; D011138:Polytetrafluoroethylene; D007052:Ibuprofen